A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

NCT03316898 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business decision to stop the study.

Conditions

Alzheimer's Disease

Interventions

DRUG: AGN-242071
DRUG: Placebo
DRUG: Donepezil
DRUG: Memantine

Sponsor

Allergan